STOCKWATCH: Reasons to be tearful

Last week was a bad week all round for investors in pharma and biotech. It wasn't only the seasonal affective disorder of quarterly reporting. It was more that, judging by share price movements, investors seemed to miss many of the good news stories buried amongst the results. And they missed bad news stories, too. And then they got confused about which was which.